Brûleur de graisse THERMOFIT Liquid
Food supplement declared in France, declaration No 2024-1-631, decision dated 15 January 2024
Brûleur de graisse THERMOFIT Liquid is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 4 rules of use apply to its ingredients (limits and warnings).
- Brand
- not provided
- Food business operator placing the product on the market
- SANTE BY NUTRITION
- Status
- Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
- Form
- Flacon
- Daily dose
- 30 ml par jour
- Directions for use
- Prendre 15 ml avant les deux principaux repas (midi et soir)
- Not recommended for (according to the manufacturer)
- Adolescents (moins de 18 ans), Femmes allaitantes, Allergie aux dérivés salicylés, À prendre en dehors des repas, Femmes enceintes, Sous anticoagulants, Sous traitement pour la thyroïde
- Objectives stated by the manufacturer (these are not authorised claims)
- Détoxifiant / Draineur, Minceur / Brûleur, Gestion du poids / minceur, Minceur / Modérateur d'appétit
Declaration 324368, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.
Regulatory points
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/2340).
- Conditions légales
Betula pendula Roth: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux personnes souffrant d'allergie aux dérivés salicylés
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Foeniculum vulgare Mill.: La portion journalière recommandée ne doit pas conduire à une ingestion d'estragole supérieure à 0,05 mg/kg de poids corporel pour les enfants de moins de 12 ans.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Camellia sinensis (L.) Kuntze | Feuille | Extrait sec aqueux | 2,700 mg |
| Betula pendula Roth | Ecorce | Extrait sec aqueux | 21 mg |
| Carica papaya L. | Fruit | Extrait sec aqueux | 21 mg |
| Cola acuminata (P.Beauv.) Schott et Endl. | Graine | Extrait sec aqueux | 21 mg |
| Cynara scolymus L. | Feuille | Extrait sec aqueux | 21 mg |
| Foeniculum vulgare Mill. | Fruit | Extrait sec aqueux | 21 mg |
| Ilex paraguariensis A. St.-Hil. | Feuille | Extrait sec aqueux | 21 mg |
| Melilotus officinalis (L.) Pall. | Parties aériennes | Extrait sec aqueux | 21 mg |
| Paullinia cupana Kunth | Graine | Extrait sec aqueux | 21 mg |
| Peumus boldus Molina | Feuille | Extrait sec aqueux | 21 mg |
| Raphanus raphanistrum subsp. sativus (L.) Domin | Racine | Extrait sec aqueux | 21 mg |
| Ribes nigrum L. | Feuille | Extrait sec aqueux | 21 mg |
| Taraxacum campylodes G.E.Haglund | Feuille | Extrait sec aqueux | 21 mg |
| Vaccinium myrtillus L. | Fruit | Extrait sec aqueux | 21 mg |
| Zingiber officinale Roscoe | Rhizome | Extrait sec aqueux | 21 mg |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| Chlorure de chrome | Chrome | pas de limite (données insuffisantes) | 25 µg |
Additives
E422, E330, E202, E211
Other ingredients
Eau potable
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Une consommation excessive peut avoir des effets laxatifs. Contient de la caféine (110 mg pour 30 ml) et des épigallocatechine gallate (EGCG) (135 mg pour 30 ml). Ne pas consommer une quantité égale ou supérieure à 800 mg d’EGCG par jour. Ce produit ne doit pas être consommé si vous prenez le même jour d’autres produits contenant du thé vert ; ne doit pas être consommé par les femmes enceintes ou allaitantes et par les enfants de moins de 18 ans ; ne doit pas être consommé à jeun. Déconseillé aux personnes sous traitement anti-coagulant ; aux personnes souffrant d’allergie aux dérivés salicylés et d’intolérance aux anti-inflammatoires non-stéroïdiens et aux personnes ayant un trouble de la thyroïde. Déconseillé en cas d’obstruction biliaire ou d’autres troubles de la fonction biliaire ; en cas d'insuffisance cardiaque ou de troubles cardiaques ; en cas d'insuffisance rénale oedèmateuses ou hépatique; en cas d'ulcère gastro-duodénal [...]
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Betula pendula Roth
Read the warning, when it applies and the studies cited
Birch
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney or cardiovascular disorders (Brinker 2010; Bradley 2006; ESCOP 2003; Blumenthal et al. 1998).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Brinker 2010).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Foeniculum vulgare Mill.
Read the warning, when it applies and the studies cited
BITTER FENNEL- FOENICULUM VULGARE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Essential oil and Tincture.
Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Health Canada monograph dated 29 November 2024
SWEET FENNEL -FOENICULUM VULGARE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2024).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Peumus boldus Molina
Read the warning, when it applies and the studies cited
BOLDO - PEUMUS BOLDUS
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney or liver disorder (Brinker 2010; Barnes et al. 2007; Bradley 2006).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant or breastfeeding (EMA 2016; Brinker 2010; Bradley 2006; Mills and Bone 2005).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Taraxacum campylodes G.E.Haglund
Read the warning, when it applies and the studies cited
DANDELION - TARAXACUM OFFICINALE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder or an intestinal obstruction (Brinker 2010; Godfrey et al. 2010; ESCOP 2003; Bradley 1992).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Constipation, Flushing of the urinary tract, Indigestion, and Loss of appetite.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Applies to products providing 10 g or more of dried leaf or dried root or dried whole plant, per day or 10 mL or more of juice, per day.
Do not use if you have diabetes or a blood pressure, kidney or cardiovascular disorder (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).
8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Do not use if you are taking heart medications or other products containing diuretics (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).
8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Vaccinium myrtillus L.
Read the warning, when it applies and the studies cited
BILBERRY - VACCINIUM MYRTILLUS - Buccal
Route of administration: Buccal (Blumenthal et al. 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 30 January 2026
BILBERRY - VACCINIUM MYRTILLUS - Oral
Route of administration: Oral (Blumenthal et al. 2000)
Cautions and warnings
Condition of application: Relief of diarrhea.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
- Zingiber officinale Roscoe
Read the warning, when it applies and the studies cited
GINGER - ZINGIBER OFFICINALE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.